biocomsystems

Simulator for Skin Pharmacokinetics

SKIN-CAD®

Simulator for Skin Pharmacokinetics

Version 6.0

SKIN-CAD[®]

Version *6.0*

Copyright (C) 2009 Biocom Systems, Inc. All Rights Reserved.

Biocom Systems, Inc.

SKIN-CAD[®] **biocom**systems


Simulator for Skin Pharmacokinetics

SKIN-CAD®

- Simulation software of pharmacokinetics following <u>transdermal drug delivery</u>
- Editor: Prof. K. Tojo (Kyushu Institute of Technology)
- Distribution from the year 2000
- 16 Japanese, US and UK users: pharmaceutical and chemical companies, and university labs (as of Aug., 2010)

[TTS (Transdermal Therapeutic System)]


SKIN-CAD[®] **biocom**systems





TTS patches: Nicotine, Fentanyl, Nitroglycerin, Estradiol, etc.

[Modeling of Transdermal Drug Delivery]

SKIN-CAD[®] **biocom**systems







[Skin permeation model]

SKIN-CAD[®] **biocom**systems


$$\{\mathbf{1} + \mathbf{B}(C_{\rm sc})\}\frac{\partial C_{\rm sc}}{\partial t} = D_{\rm sc}\frac{\partial^2 C_{\rm sc}}{\partial x^2} + \mathbf{ER}(C_{\rm sc}) + \mathbf{EO}(C_{\rm sc})$$

for stratum corneum, 0 < x < h

$$\{1 + \mathbf{B}(C_{vs})\}\frac{\partial C_{vs}}{\partial t} = D_{vs}\frac{\partial^2 C_{vs}}{\partial x^2} - \mathbf{M}(C_{vs}) + \mathbf{EO}(C_{vs})$$

for viable skin, h < x < H

- Skin binding, B(C): Langmuir-type or Freundlich-type scheme
- Skin metabolism, M(C): Michaelis-Menten or First-order kinetics



[Body PK-PD model]

SKIN-CAD[®] **biocom**systems

1-, 2- or 3-compartment model (pharmacokinetics, PK)

$$V_1 \frac{\mathrm{d}C_1}{\mathrm{d}t} = \left(\frac{\mathrm{d}Q}{\mathrm{d}t}\right) S_a - (k_{10} + k_{12} + k_{13}) C_1 V_1 + k_{21} C_2 V_2 + k_{31} C_3 V_3$$


$$V_2 \frac{\mathrm{d}C_2}{\mathrm{d}t} = k_{12}C_1V_1 - k_{21}C_2V_2 \qquad V_3 \frac{\mathrm{d}C_3}{\mathrm{d}t} = k_{13}C_1V_1 - k_{31}C_3V_3$$

V: distribution volume [mL], k₁₀: elimination rate constant [s⁻¹],
k: transfer rate constant [s⁻¹], S_a: system size [cm²],

dQ/dt: skin permeation flux [mg/cm²/s]

Pharmacokinetic (PK) - pharmacodynamic (PD) model

Direct response model Effect compartment model Indirect response model



SKIN-CAD[®] biocom_{systems} [Case study: Fentanyl patch (1/3)] In vitro matrix release and skin permeation studies Skin TŢS Receptor cell Water jacket Diffusion cell system Cell volume: 5.0 ml Effective area: 0.64 cm2 Fig. 1. Experimental Apparatus for in Vitro Skin Permeation Experiment 888888 VIDREX Cumulative amount permeated Stripped skin data $\frac{\mathrm{d}Q}{\mathrm{d}t}$ Hairless mouse $\left(\frac{\mathrm{d}Q}{\mathrm{d}t}\right)_{W}$ Intact skin data

Time

[Case study: Fentanyl patch (2/3)]

SKIN-CAD[®] **biocom**systems

Simulation of blood concentration under human clinical condition

- Model: Matrix/skin 2-layer diffusion model
- Matrix release parameters
 - Application period: 72 h
 - $D_{\rm m}$: Determined by in vitro matrix release study
 - System size, thickness, and initial drug content
- Skin permeation parameters

Thickness of stratum corneum, $h = 20 \ \mu m$

Distance to dermal microcirculation, $H = 200 \ \mu m$

 $D_{\rm sc}, D_{\rm vs}, K_{\rm sc/vs}, C_{\rm s}$:


Determined by in vitro skin permeation study using hairless mouse skin

- 3-Compartmental PK parameters (obtained from ref.: Bentley et al., 1982)
 - $V_1 = 18.3 \text{ L}, V_2 = 51.9 \text{ L}, V_3 = 214 \text{ L}$

 $k_{10} = 2.76 \text{ h}^{-1}, k_{12} = 19.1 \text{ h}^{-1}, k_{21} = 6.73 \text{ h}^{-1}, k_{13} = 7.90 \text{ h}^{-1}, k_{31} = 0.674 \text{ h}^{-1}$

[Case study: Fentanyl patch (3/3)]


SKIN-CAD[®] **biocom**systems



Comparison between simulated and clinical data



SKIN-CAD[®] **biocom**systems



Prediction of clinical performance based on *in vitro* data
Optimal design and evaluation of TTS at early stage
R&D at a lower cost and in a shorter period